Furthermore, PF-04136309, a CCR2 inhibitor, was shown to reduce CCR-2+/CD14+ monocytes and macrophages in the pre-metastatic liver and primary pancreatic tumor. Here, CCR2 is linked to pancreatic neoplasm.